We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA approved Fasenra (benralizumab) for HES therapy. 65% reduction in exacerbation risk and steroid-sparing effect. Learn how this changes the biosimilar market.
